ÂÜÀòÂÒÂ×

Justin Scheer is a seasoned expert in biotherapeutics and computational biology, currently serving as the Vice President of In Silico Discovery at Johnson & Johnson Innovative Medicine since December 2023. With a robust background in AI and machine learning applications for drug discovery, Justin leads a global team focused on various therapeutic modalities including small molecules, peptides, and gene therapies. Previous roles include Vice President positions at The Janssen Pharmaceutical Companies of Johnson & Johnson, and key leadership positions at Boehringer Ingelheim and Genentech, where responsibilities spanned antibody engineering, bioinformatics, and therapeutic development. Justin's academic credentials include a PhD in Biochemistry, Biophysics, and Molecular Biology from Washington State University and postdoctoral research at the University of California, San Francisco.